Zinc gluconate
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Zinc gluconate
- Molecular weight
- 455.68
- Structure (SMILES)
- O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Zn+2]
- bis d gluconato o1 o2 zinc
- Bis(d-gluconato-o1,o2) zinc
- gluconic acid zinc complex
- Gluconic acid zinc complex
- GLUCONIC ACID ZINC COMPLEX [MI]
- gluconic acid zinc complex mi
- zinc d gluconate 1 2
- Zinc d-gluconate (1:2)
- zinc gluconate
- Zinc gluconate
- ZINC GLUCONATE [EP IMPURITY]
- ZINC GLUCONATE [EP MONOGRAPH]
- ZINC GLUCONATE [FCC]
- ZINC GLUCONATE [GREEN BOOK]
- ZINC GLUCONATE [HSDB]
- ZINC GLUCONATE [MART.]
- ZINC GLUCONATE [USP MONOGRAPH]
- ZINC GLUCONATE [VANDF]
- Zinc gluconate [WHO-DD]
- zinc gluconate ep impurity
- zinc gluconate ep monograph
- zinc gluconate fcc
- zinc gluconate green book
- zinc gluconate hsdb
- zinc gluconate mart
And 7 more, listed on the interactive page.
- ATC classification codes
- A12CB02
Sources for recorded values
- CAS registry numbers
- 4468-02-4
- ChEMBL ID
- CHEMBL3833377
- InChIKey
- WHMDKBIGKVEYHS-IYEMJOQQSA-L
- RxNorm IDs (RxCUI)
- 58300
- FDA ingredient codes (UNII)
- U6WSN5SQ1Z
- 443445
- 452949
- First in class
- No
- Orphan designation
- No
- Condition
- Jaundice, Neonatal
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000739
- Subject identifier
- D007567
- Condition
- Dysphonia
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0000485
- Subject identifier
- D055154
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Hepatolenticular Degeneration
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0010200
- Subject identifier
- D006527
- Condition identifier
- EFO_0000280
- Highest recorded phase
- 1
- Condition identifier
- EFO_1000003
- Condition identifier
- EFO_1000739
- Condition identifier
- EFO_1000739
- Highest recorded phase
- 1
- Condition identifier
- HP_0000360
- Condition identifier
- HP_0000952
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000257
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000485
- Condition identifier
- MONDO_0000485
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001209
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0010200
- Condition identifier
- MONDO_0010200
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0013098
- Event
- acne fulminans
- Reports
- 2
- Reporting signal score
- 9.96248
- Event
- ageusia
- Reports
- 21
- Reporting signal score
- 67.0803
- Event
- anaemia macrocytic
- Reports
- 3
- Reporting signal score
- 8.92787
- Event
- anosmia
- Reports
- 41
- Reporting signal score
- 198.96
- Event
- asthma
- Reports
- 8
- Reporting signal score
- 7.10929
- Event
- beta haemolytic streptococcal infection
- Reports
- 14
- Reporting signal score
- 73.2643
- Event
- blood calcium decreased
- Reports
- 4
- Reporting signal score
- 7.29276
- Event
- bone marrow eosinophilic leukocyte count increased
- Reports
- 1
- Reporting signal score
- 6.73297
- Event
- burning sensation
- Reports
- 9
- Reporting signal score
- 12.1782
- Event
- candida infection
- Reports
- 7
- Reporting signal score
- 16.405
- Event
- chest discomfort
- Reports
- 10
- Reporting signal score
- 9.04576
- Event
- chronic sinusitis
- Reports
- 7
- Reporting signal score
- 25.966
- Event
- condition aggravated
- Reports
- 25
- Reporting signal score
- 20.5887
- Event
- congenital anomaly
- Reports
- 6
- Reporting signal score
- 16.7081
- Event
- copper deficiency
- Reports
- 14
- Reporting signal score
- 104.836
- Event
- creatinine renal clearance decreased
- Reports
- 4
- Reporting signal score
- 9.71459
- Event
- crystal nephropathy
- Reports
- 2
- Reporting signal score
- 7.50129
- Event
- diastolic dysfunction
- Reports
- 7
- Reporting signal score
- 24.8743
- Event
- disease recurrence
- Reports
- 7
- Reporting signal score
- 11.3094
- Event
- diverticulum
- Reports
- 7
- Reporting signal score
- 18.1264
- Event
- drug intolerance
- Reports
- 10
- Reporting signal score
- 7.4379
- Event
- dysgeusia
- Reports
- 7
- Reporting signal score
- 7.45918
- Event
- dyspnoea exertional
- Reports
- 8
- Reporting signal score
- 12.0398
- Event
- eczema
- Reports
- 7
- Reporting signal score
- 12.2221
- Event
- embolism venous
- Reports
- 7
- Reporting signal score
- 24.2782
And 53 more, listed on the interactive page.
- NCT00692224
- NCT01309620
- NCT03957720
- NCT05892770
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 27
- Molecular formula
- C12H22O14Zn
- Monoisotopic mass
- 454.030097
- Natural product
- Yes
- 17312-077
- 52796-173
- 52796-174
- 52796-177
- Recorded assays
- 1
- Active assays
- 0
- Trace Elements
Related records
Trials (11)
- Effect of Zinc on Barrett's Metaplasia
- Effect of Zinc on Glucose Homeostasis
- Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease
- Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss
- The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction
- The Individual Therapy for Patients With Wilson's Disease
- Zinc Effect on Inflammation and Cardiovascular Risk in HIV
- Zinc Intervention in Elderly for Prevention of Pneumonia
- Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia
In development for (4)
- Barrett esophagus Phase 1
- Spasmodic dystonia Phase 1
- Type 2 diabetes mellitus Phase 2
- Wilson disease Early phase 1